← Back to Clinical Trials
Recruiting NCT03302195

Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Cardiopulmonary Bypass
Sponsor Laval University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 410
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2015-08-21
Completion 2024-12-31
Interventions
Heparincardiopulmonary bypass pump flow rate

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Standard Heparin management, based on total body weight, is not well established for obese patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). The purpose of this study is to assess the safety and efficacy of using lean body mass (LBM) to determine pump flow rate and/or Heparin dosage in obese patients undergoing CPB.

Eligibility Criteria

Inclusion Criteria: * Obese patients (BMI ≥ 30kg/m2) * Planned cardiac surgery * Age ≥ 18 years Exclusion Criteria: * Permanent pacemaker * Known intolerance to protamine * Known or suspected allergy to the used antifibrinolytic agent * Refusal to receive blood products * Planned off pump coronary artery bypass * Planned peri-operative use of desmopressin * Known Heparin-induced thrombocytopenia * Known deficiency in protein C, protein S, antithrombin or homozygous factor V Leiden * Known congenital bleeding disorders * Current endocarditis * Planned hypothermic circulatory arrest (\<28C) * Two or more cardiac surgery procedures * Emergency cardiac surgery procedures (medically required within 24hours of presenting with acute symptoms) * Planned CPB priming with red blood cells * Any known autoimmune disease * Any history of stroke or non-coronary thrombotic disorders including deep venous thrombosis and pulmonary embolism * Significant (≥50%) carotid artery stenosis * Patient dosed wi

Related Trials

}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology